Paper Details

  1. Home
  2. Paper Details

The FDA-approved anti-cancer drugs, streptozotocin and floxuridine, reduce the virulence of Staphylococcus aureus.

Author: AryaRekha, BaeTaeok, ChoKyu Hong, JeongHyunyoung, KimKyeong Kyu, YeoWon-Sik

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Streptozotocin (STZ) and floxuridine (FU), two anti-cancer drugs, were identified as potential anti-virulence drug candidates against Staphylococcus aureus infection. FU was more efficient than STZ in repressing Sae-regulated promoters and protecting human neutrophils from S. aureus-mediated killing. Both compounds showed in vivo efficacy in murine models of infection without noticeable side effects.
Paper Details　
Original Abstract of the Article :
In Staphylococcus aureus, an important Gram-positive human pathogen, the SaeRS two-component system is essential for the virulence and a good target for the development of anti-virulence drugs. In this study, we screened 12,200 small molecules for Sae inhibitors and identified two anti-cancer drugs,...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802796/

データ提供：米国国立医学図書館（NLM）

Anti-Cancer Drugs: A New Weapon Against Staphylococcus aureus Infections

Staphylococcus aureus, a common and potentially dangerous bacteria, can be likened to a desert sand viper, silently lurking and waiting to strike. This study explores the potential of two FDA-approved anti-cancer drugs, streptozotocin and floxuridine, to combat infections caused by S. aureus. The study investigates the ability of these drugs to inhibit the SaeRS two-component system, which is crucial for the virulence of S. aureus. The research also examines the efficacy of these drugs in protecting human cells from S. aureus-mediated killing.

Turning the Tables on the Sand Viper

The research found that streptozotocin and floxuridine effectively inhibited the SaeRS system and protected human neutrophils from S. aureus-mediated killing. Furthermore, these drugs demonstrated in vivo efficacy in a murine model of blood infection. This study offers a novel approach to combating S. aureus infections, using existing anti-cancer drugs to target virulence factors and protect the body from the harmful effects of these bacteria. It's like finding a hidden antidote for the venom of a desert sand viper, turning the tables on this dangerous foe.

Navigating the Shifting Sands of Antibiotic Resistance

This study highlights the importance of finding new ways to combat antibiotic resistance, a growing threat to global health. The research suggests that repurposing existing drugs, like streptozotocin and floxuridine, could be a promising strategy for developing new anti-virulence drugs. It's a reminder that the desert of antibiotic resistance is constantly shifting, and we must constantly seek new approaches to overcome this challenge.

Dr. Camel's Conclusion

This research offers a promising new avenue for combating S. aureus infections. The repurposing of existing anti-cancer drugs as anti-virulence agents could represent a significant step forward in the battle against this dangerous bacteria. This research is a testament to the power of creative thinking and the dedication to finding solutions for some of the most pressing health challenges of our time.

Date :
  1. Date Completed 2019-09-30
  2. Date Revised 2019-09-30
Further Info :

Pubmed ID

29410445

DOI: Digital Object Identifier

PMC5802796

Related Literature

Article Analysis
・Side Effects of streptozocin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.